Zheijang Hisun Pharma will not pursue its option to secure China rights for ThermoDox®, the heat-triggered chemotherapy treatment for liver cancer, from Celsion. As the first part of the process, Hisun paid $5 million toward the option about one month ago. Last week, Celsion announced ThermoDox did not meet its primary endpoint in a global Phase III trial. The two parties will examine the data from the China sites to see if there is any reason to seek approval of the drug in China. More details.... Stock Symbols: (SHA: 600267) (NSDQ: CLSN) Share this with colleagues: // //